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Summary
Purpose: In this study we examined the expression levels 
of miR-17 which possesses oncogenic activities through 
downregulation of CDKN1A, p21 and E2F1 tumor sup-
pressor genes,  in imatinib sensitive and resistant chronic 
myeloid leukemia (CML) cells. On the other hand, we also 
determined the expression levels of miR-17 in response to 
tyrosine kinase inhibitors imatinib, nilotinib and dasatinib 
used for the treatment of CML.
Methods: The expression profiles of miR-17 were analysed 
by Stem-Loop reverse transcription (RT) polymerase chain 
reaction (PCR). 
Results: The results revealed significant increase in the ex-
pression levels of miR-17 in imatinib sensitive and resistant 
cells compared to peripheral blood mononuclear cells (PB-
MCs). On the other hand, significant decrease was observed in 
miR-17 levels in response to imatinib, nilotinib and dasatinib.
Conclusion: These results may imply that miR-17 can be 
used for diagnosis and treatment of CML.
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Introduction
miRNAs are about 20-22 nucleotides long, 
single-stranded, non-protein-coding RNA mole-
cules [1]. This abundant class of small RNA mol-
ecules is found in most of the animal and plant 
cells [2]. They are supposed to play critical roles in 
gene regulation and they downregulate the target 
genes either by degrading the target mRNAs with 
their perfect match with the cognate mRNAs or 
by inhibiting the translation of the target mRNAs 
due to their imperfect complementarity with cog-
nate mRNAs [3,4].
Transcription of miRNA genes that are encod-
ed within the genome of eukaryotic organisms be-
gins in the nucleus, when the transcription factors 
bind to the promoter of miRNA genes. In this way, 
primary-miRNA (pri-miRNA) is formed and then 
it is converted into precursor–miRNA (pre-miR-
NA) by Drosha. The newly formed pre-miRNAs are 
then transferred from the nucleus to cytoplasm 
by RanGTP-dependent dsRNA-binding protein 
(Exportin 5). After the transfer of the pre-miRNAs 
to the cytoplasm through the exportin trans-
fer system, the pre-miRNAs are cleaved to form 
miRNA:miRNA duplexes which are between 19-
24 base pairs, by the ribonuclease (RNase) Dicer. 
Dicer is known as an endoribonuclease belonging 
to RNase III protein family that cleaves dsRNAs 
and pre-miRNAs into short, dsRNA fragments and 
it has the potential to form RNA-inducing silenc-
ing complex (RISC) which recognizes the mature 
miRNA, while the complementary region of the 
mature miRNA is degraded. The incorporated 
miRNA into the RISC complex is directed to the 
target mRNA for degradation or the inhibition of 
translation of it [1,5,6]. 
 Inhibition of the translation of target 
mRNAs or even degradation of them by miRNAs 
make these specific RNA fragments crucial and 
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potential targets for anticancer therapy [7]. It has 
been shown that each miRNA has its signature 
for a specific malignancy and normal tissue [8]. 
It has been also revealed that the abnormal gene 
expression of some miRNAs playing critical roles 
as oncomiRs in some tissues can result in cancer 
development and progression [8]. Thus, the de-
tection of these types of miRNAs seems to be an 
important step for the detection and classification 
of various cancer types or even prediction of their 
severity [9].
miR-17 family which is within the miR-17-
92 cluster, has crucial oncogenic activities in dif-
ferent cancer cell types, including CML [10,11]. 
Overexpression of miR-17 in various types of can-
cer emphasizes its roles in clinical diagnosis and 
treatment of cancers [10,11]. 
CML is characterized by the increased num-
ber of myeloid cells in the peripheral blood, re-
sulting from malignant disorder of hematopoietic 
stem cells [12-14]. CML is characterized with the 
presence of Philadelphia (Ph) chromosome, origi-
nating from the reciprocal translocation between 
ABL1 gene on chromosome 9q34 and BCR gene 
on chromosome 22q11.2 [12-14]. The resulting 
BCR/ABL oncogene induces leukemogenesis with 
its constitutive tyrosine kinase activity [15].
Imatinib, nilotinib and dasatinib are antican-
cer agents used for the treatment of CML. They 
specifically recognize, bind and inactivate tyros-
ine-kinase activity of the BCR/ABL oncoprotein 
and thus inhibit leukemogenesis [12,13].
Recent miRNA-dependent cancer studies are 
based on the comparison of the expression levels 
of specific miRNAs in different cancer cell types 
with normal cells in the same tissue [4]. Thus, re-
garding the specific miRNA expression profiles 
in specific tumors, abnormal upregulation (on-
comiRs) or downregulation (tumor-suppressor 
miRNAs) of particular miRNAs in various cancer 
types are addressed for classifying human cancer 
types [4]. Although for the detection of miRNA 
profiles the techniques of cloning, northern blot-
ting and microarray are commonly used, it has 
been argued that their efficiency in detecting quite 
small amounts of miRNAs is low [16]. That’s why 
Stem-Loop RT-PCR which is quick, efficient and 
exact for the detection of miRNA gene profiling is 
proposed [16]. Since the specific primers are used 
in this new technique, it is quite sensitive and 
efficient to detect even one nucleotide difference 
within the specific miRNAs, distinguish homolo-
gous miRNAs, and overcome low throughput of 
convential techniques besides not being affected 
from DNA contamination [16,17].
 In the present study, we aimed to exam-
ine the expression levels of miR-17 in the PBMCs 
and in the imatinib sensitive and resistant CML 
cells by Stem-Loop RT-PCR. We also determined 
the expression levels of miR-17 in CML cells in 
response to tyrosine kinase inhibitors imatinib, 
nilotinib and dasatinib.
Methods 
Ethical permission of this study was obtained from 
Ege University, Faculty of Medicine, Clinical Research 
Ethical Comission.
Target and primers
 miR-17 was specifically selected from the mi-
croRNA database miRBase (http://www.mirbase.org). 
miR-17 and U6 snRNA, an internal positive control, 
stem-loop reverse transcriptases, forward and reverse 
primers were designed manually according to Chen et 
al. [16].  
hsa-miR–17 miRNA sequence 5’-CAAAGUGCUUA 
CAGUGCAGGUAG-3’; 
Stem-Loop RT Primer 
3’-TCCATCCAACCGAGACCACGCTTATGGAGCCTGGGA 
CGTGGTCTCGGTTG-5’;  
Forward Primer 
5’-CGGCAAAGTGCTTACAGTGC-3’ 
Universal Reverse Primer 
5’-GTGCAGGGTCCGAGGT-3’; 
UPL Probe 
5’-TGGCTCTG-3’.
U6 snRNA Stem-Loop Primer 
5’-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACA 
GAGCCAACACGATT-3’; 
Forward Primer 
5’-CCTGCGCAAGGATGAC-3’; 
Reverse Primer 
5’-GTGCAGGGTCCGAGGT-3’; 
UPL Probe 
5’-TGGCTCTG-3’.
Peripheral blood mononuclear cell isolation
PBMCs were isolated from the blood of a healthy 
donor from our lab. Eight ml of blood were mixed with 
32 ml phosphate buffered saline (PBS). Then, the di-
luted blood was transferred carefully over 12 ml of 
Ficoll-Paque in 50 ml falcon tube and centrifuged at 
2500 rpm for 25 min at 20 0C. After centrifugation, the 
mononuclear cell layer was carefully transferred into 
a new falcon tube and PBMCs were washed. After cen-
trifugation at 1600 rpm for 10 min at 4 0C, the superna-
tant was removed carefully and this step was repeated 
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for three times. Finally, the PBMC pellet was diluted 
with 10 ml of PBS and cells were counted using Thoma 
Counting Chamber.
 Cell lines and conditions of cell culture
Human K562 CML cells were obtained from the 
German Collection of Microorganisms and Cell Cul-
tures (Germany). Subpopulations of K562 cells that 
could grow in the presence of 3 µM imatinib (referred 
to as K562/IMA-3) were developed in our research lab-
oratory [18]. K562 and K562/IMA-3 cells were grown 
in RPMI 1640 medium containing 10% fetal bovine se-
rum (FBS) and 1% penicillin-streptomycin in CO2 incu-
bator at 37 0C. The medium was refreshed three times 
in a week.
Total RNA isolation
RNA isolation process was performed using Tri-
zol Reagent for obtaining miRNAs efficiently, since it is 
more sensitive to small RNA fragments and miRNAs. 
2x106 PBMC, K562 and K562/IMA-3 cells were collect-
ed and centrifuged at 1000 rpm for 10 min. After re-
moving the supernatant from the pellets, 1 ml Trizol 
Reagent was added to each cell tube. The pellets were 
lysed by repetitive pipetting and incubated at 20 0C for 
5 min. Then, 0.2 ml chloroform was added to the ho-
mogenized mixture and incubated at 20 0C for 3 min. 
Afterwards, samples were centrifuged at 12000 g for 
10 min at 4 0C. The RNA containing upper phase was 
transferred into a new eppendorf tube and 0.5 ml iso-
propyl alcohol was added to the tube. Samples were in-
cubated at 20 0C for 5 min and centrifuged at 12000 g 
for 10 min at 4 0C. After centrifugation, RNAs observed 
were washed with 1 ml of 75% ethanol, vortexed and 
centrifuged at 7500 g for 5 min at 4 0C. Finally, RNAs 
were resuspended with 40 µl of RNase-free distilled 
H 2O and the quality and amount of each sample was 
measured by Nanodrop ND-2000 spectrophotometer 
(Thermo Scientific, DE, USA).
Reverse transcriptase reactions and real-time PCR 
Stem-loop RT-primers specifically designed for 
miR-17 and U6 snRNA were used instead of random 
primers. After the mixtures for each sample were pre-
pared, they were incubated at 25 0C for 10 min, at 42 0C 
for 1 h, at 70 0C for 10 min, and then stored at 4 0C. The 
mixture for reverse transcriptase reactions was 1 µl 
Stem-Loop RT-Primer (1µM, for miR-17 or U6 snRNA), 
total RNA (50 ng), 1 µl  dNTP mixture (10 mM), 1 µl 
RNase inhibitor (50 U/µl), 4 µl  Reverse Transcriptase 
Buffer (10X), 1 µl  Reverse Transcriptase (200 U/µl) and 
RNase-free dH2O up to 20 µl.
 For RT-PCR reactions, specifically designed 
forward and reverse primers of miR-17 and U6 snRNA 
were used. The reactions were run at 50 0C for 2 min, at 
95 0C for 10 min, then at 95 0C for 15 sec, at 59 0C for 30 
sec, at 72 0C for 30 sec x 40 cycles and finally at 72 0C 
for 10 min in LightCycler Real-Time PCR Machine. The 
mixture of the reactions was prepared as follows: 12.5 
µl SYBR Green Mix (2X), 1 µl primer mix (forward and 
reverse primers for miR-17 and U6 snRNA, 5 pmol), 1 
µl reverse transcript, 10.5 µl distilled H2O. All reactions 
were performed in triplicate.
Statistics
The change of miR-17 gene expression profiling 
was analysed by using the Livak method (ΔΔCT meth-
od). For realizing the Livak method to the samples, 
there are 3 steps to follow. These are normalization of 
the Ct value of the target gene to the Ct value of the ref-
erence gene, normalization of the ΔCt value of the test 
sample to the ΔCt value of calibrator, and calculation of 
the expression difference which is fold change. 
Results 
Significant increase was observed in K562 and K562/
IMA-3 cells
We generated K562/IMA-3 cells that showed 
52-fold more resistant to imatinib as compared to 
parental sensitive K562 cells previously [18]. In 
this study, we aimed to examine the changes in 
expression levels of miR-17 in healthy, imatinib 
sensitive and resistant cells.
The results showed that Ct values were down 
in CML cells, revealing that the expression levels 
of miR-17 were going up in CML cells as com-
pared to healthy PBMCs while there were no sig-
nificant changes in the expression levels of U6 
snRNA (Figure 1).
1. ΔCt (PBMC) = Ct (miR-17, PBMC) – Ct (U6 sn-
RNA, PBMC)ΔCt (PBMC) = 22.5 – 27.3 = -4.8 
ΔCt (K562) = Ct (miR-17, K562) - Ct (U6 snR-
NA, K562) 
ΔCt (K562) = 17.7 – 26.2 = -8.5    
2. ΔΔCt = ΔCt (K562) - ΔCt (PBMC) 
= -8.5 – (- 4.8) = -3.7
3. 2-ΔΔCt = Normalized fold change 
2-(-3.7) = 12.99
Figure 1. Changes in Ct values in PBMC, K562 and 
K562/IMA-3 cells.
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The calculated fold change indicated that K562 
cells expressed miR-17 12.99-fold higher than 
PBMCs (Figure 2). 
ΔCt (PBMC) = Ct (miR-17. PBMC) – Ct (U6 snR-
NA, PBMC)
ΔCt (PBMC) = 22.5 – 27.3 = -4.8
ΔCt (K562/IMA-3) = Ct (miR-17, K562/IMA-3) -  
   Ct (U6 snRNA, K562/IMA-3)
ΔCt (K562/IMA-3) = 19.2– 26.8 = -7.6            
ΔΔCt = ΔCt (K562/IMA-3) - ΔCt (PBMC)
= -7.6 – ( - 4.8 ) = -2.8
2-ΔΔCt = Normalized fold change
2-(-2.8) = 6.96
The calculated expression difference indicat-
ed that K562/IMA-3 cells expressed miR-17 at a 
6.96-fold level higher than PBMCs (Figure 2).
 
ΔCt (K562/IMA-3) = -7.6 
ΔCt (K562) = -8.5 
ΔΔCt = ΔCt (K562-sensitive) - ΔCt (K562 imatin-
ib-resistant) = -8.5 – ( -7.6 ) = -0.9 
2-ΔΔCt = 2-(-0.9) = 1.87
The expression levels of miR-17 were 1.87-fold higher 
in K562 cells as compared to K562/IMA-3 cells (Fig-
ure 2).
Tyrosine kinase inhibitors decreased the ex-
pression levels of miR-17 in a dose-dependent 
manner in K562/IMA-3 cells
The effects of nilotinib and dasatinib on the 
expression level of miR-17 in K562/IMA-3 cells 
were also examined. The average Ct values were 
calculated for each sample (Figure 3). The results 
showed that Ct values were going up in response 
to imatinib, dasatinib and nilotinib treatment, in-
dicating that the expression levels of miR-17 were 
going down after drug treatment, while there were 
no significant changes in the expression levels of 
U6 snRNA (Figure 3).
The fold changes in the expression of miR-17 
in each sample were calculated by using the Li-
vak method by normalizing each sample to K562/
IMA-3 cells. As shown in Figure 4, there was 77% 
decrease in the expression levels of miR-17 in re-
sponse to 5 µM imatinib as compared to K562/
IMA-3 cells and normalized to U6 snRNA. On the 
other hand, 87 and 90% decreases in the expres-
sion levels of miR-17 were detected in K562/IMA-
3 cells treated with 2 and 5 µM nilotinib, respec-
tively (Figure 4), while 0.2 and 0.5 µM dasatinib 
application resulted in 93 and 96% decreases in 
the expression levels of miR-17, respectively.
 These results showed that imatinib, nilo-
tinib and dasatinib reduce the expression of miR-
17 in imatinib-resistant CML cells. On the other 
hand, extreme fold changes in the expression lev-
els of miR-17 in CML cells in the presence of dif-
ferent tyrosine kinase inhibitors treatment proved 
that miR-17 may be a crucial target for the treat-
ment of CML.
Figure 2. Fold changes in expression levels of miR-17 
in PBMC, K562, 3 µM imatinib treated K562, K562/IMA-
3, and 5µM imatinib treated K562/IMA-3 cells.
Figure 3. Changes in Ct values in K562/IMA-3 cells 
treated with imatinib, dasatinib and nilotinib.
Figure 4. Percent changes in expression levels of miR-
17 in K562/IMA-3 cells treated with imatinib, dasatinib 
and nilotinib.
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Discussion
It was shown by Zhang et al. that miR-17 plays 
critical roles in the proliferation and metastasis of 
colon cancer [19]. It was also demonstrated that 
miR-17 can be used as a molecular marker for the 
detection of gastric cancer [20]. Additionally, miR-17 
has oncogenic role in colorectal carcinoma cells as 
compared to the normal tissues and hence it could 
be accepted as a therapeutic target for the treatment 
of colorectal carcinoma [21].
 Taking together, the results of our group 
and of some other groups show that miR-17 has 
significant roles in the initiation of cancer. Thus, 
this study is important in showing the involvement 
of miR-17 in the initation of CML, and the devel-
opment of drug resistance. Treatment of CML cells 
with different concentrations of imatinib, nilotinib 
and dasatinib reduced the expression levels of miR-
17 in drug-resistant cells. Since the upregulation of 
miR-17 was detected in CML cells, miR-17 can be 
used as a diagnostic and/or therapeutic target for de-
tection and/or treatment of CML.
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